- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03037398
Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation (CLOVER)
April 2, 2025 updated by: Boston Scientific Corporation
The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
- University Berlin, Charite Virchow Standort, Wedding
-
Hamburg, Germany
- Universitaetsklinik Eppendorf
-
Kiel, Germany
- Universitätsklinikum Campus Kiel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Implanted bilaterally in STN or GPi with a Vercise™ DBS system for Parkinson's disease, including directional leads, for at least four months and programming optimized according to standard of care with no changes to electrode configuration of primary settings for at least four weeks.
- Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
- Be at least 18 years of age.
- Device must have been implanted on label or must be on label by the time the subject gets enrolled.
Key Exclusion Criteria:
- Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Novel Arm
Programming completed by a novel method
|
|
|
Other: Standard of Care Arm
Programming completed as Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in time to program between the two arms at Programming Visit
Time Frame: at least four months post implant
|
at least four months post implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Natalie Bloom Lyons, Boston Scientific Neuromodulation Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2017
Primary Completion (Actual)
April 2, 2025
Study Completion (Actual)
April 2, 2025
Study Registration Dates
First Submitted
January 12, 2017
First Submitted That Met QC Criteria
January 27, 2017
First Posted (Estimated)
January 31, 2017
Study Record Updates
Last Update Posted (Actual)
April 3, 2025
Last Update Submitted That Met QC Criteria
April 2, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Bezmialem Vakif UniversityIstanbul University - CerrahpasaNot yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
Clinical Trials on Vercise Deep Brain Stimulation System
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
University Hospital FreiburgBoston Scientific CorporationCompleted
-
Mustafa Kemal UniversityUnknown
-
Boston Scientific CorporationRecruitingDystoniaGermany, Italy, Poland, Spain, United Kingdom, Canada, Hungary, Belgium, Israel, Netherlands, Russia, South Korea
-
Boston Scientific CorporationRecruitingParkinson's DiseaseUnited States, Germany, Belgium, Italy, Poland, Spain, Austria, France, Israel, United Kingdom, Canada, Hungary, South Korea, Turkey (Türkiye), Argentina
-
University of California, DavisRecruiting
-
Wuerzburg University HospitalUnknownParkinson Disease | DementiaGermany
-
University Hospital FreiburgBoston Scientific CorporationCompletedTreatment-resistant DepressionGermany, France
-
University of Sao Paulo General HospitalRecruitingParkinson Disease | Mild Cognitive ImpairmentBrazil
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom